BACKGROUND
The thiazolidinedione peroxisome proliferatoractivated receptor γ agonists are used for glycemic control in patients with type 2 diabetes mellitus. Studies have indicated, however, that these agents have a poor cardiovascular safety profile and are reportedly associated with increased fluid retention leading to congestive heart failure (CHF).
OBJECTIVE
To establish whether there is an association between thiazolidinedione use and increased risk of CHF and cardiovascular death in patients with prediabetes and type 2 diabetes mellitus.
DESIGN AND INTERVENTION
This was a meta-analysis of double-blind, randomized, controlled trials of thia zolinediones. The authors carried out a search of the MEDLINE and EMBASE databases, the Cochrane Library, the Database of Abstracts of Reviews and Effects, and the databases of the European Society of Cardiology, the American Heart Association, the American College of Cardiology, and the American Diabetes Association for studies published in English between January 1998 and March 2007. Search terms, used in various combinations, included "congestive heart failure", "CHF", "cardiovascular", "mortality", "cardiac", "heart", "death", "thia zolidinediones", "rosiglitazone", and "pio glitazone". Nonrandomized trials and studies in which outcomes were not reported were excluded. Pooled relative risks for cardio vascular death and CHF were Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death? calculated using the DerSimonian and Laird random effects models.
OUTCOME MEASURES
The main outcome measures were cardio vascular death and development of CHF.
RESULTS
The database search identified 661 original studies that were relevant to the aim of the metaanalysis, of which 654 were excluded because they did not report on one or both of the outcome measures or because they were not randomized. The final meta-analysis included seven studies, all of which were published between 2005 and 2007. The median trial population size was 4,351 (range 200-5,269) with a total meta-analysis population of 20,191 patients (thiazolidinedione-treated patients = 9,360; controls = 10,831). The mean length of followup was 29.7 months (range 12.0-48.0 months). The mean age of patients was 59.4 years (range 54.7-64.0 years) and the majority of patients were male (64.8%) and white (83.0%). The incidence of CHF was higher among patients with prediabetes or type 2 diabetes mellitus receiving thia zolidinediones than among control patients (2.3% versus 1.4%, relative risk [RR] 1.72, 95% CI 1.21-2.42, P = 0.002). By contrast, there was no significant difference in the RR of cardio vascular death between patients with prediabetes or type 2 diabetes mellitus taking thiazolidinediones and controls (0.7% versus 0.7%, RR 0.93, 95% CI 0.67-1.29, P = 0.68). Analysis of pooled data demonstrated that the increased risk of CHF was similar for both pio glitazone and rosiglitazone.
CONCLUSION
Thiazolidinedione use by patients with pre diabetes or type 2 diabetes mellitus is associated with an increased risk of CHF, but this observation did not equate to an increased risk of cardiovascular death.
The meta-analysis by Lago et al. has brought further valuable information to a highly controversial topic. Indeed, several meta-analyses (cited by Lago et al.) have already called into question the safety of rosiglitazone with regard to possible risks of myocardial infarction and cardiovascular mortality. None of the clinical trials included in these meta-analyses was designed to specifically evaluate the cardiovascular safety (or efficacy) of rosiglitazone, however, and the interim analy sis of the ongoing Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial did not report any increased cardiovascular mortality. 1 Similarly, Lago et al. found no increased risk of cardio vascular mortality associated with either rosiglitazone or pioglitazone when compared with placebo or a reference oral antidiabetic compound. In addition, there was no apparent difference between the two thiazolidinediones (RR = 0.91 for rosiglitazone and 1.01 for pio glitazone), although no head-to-head comparative trials were available.
The risk of CHF is a well-recognized complication reported in both RECORD with rosiglitazone 1 and PROspective pio glitAzone Clinical Trial In macroVascular Events (PROactive) with pioglitazone. 2 In the meta-analysis of Lago et al., patients given thia zolidinediones had an increased RR of CHF across a wide background of cardiovascular risk (overall = 1.74, pioglitazone = 1.32, and rosiglitazone = 2.41). These findings have led to a stronger 'black box' warning in the prescribing information for the thia zolidinediones. Nevertheless, the absence of increased cardiovascular mortality suggested that CHF in patients given thiazolidinediones might not carry the same high risk that is usually asso ciated with CHF caused by progressive dysfunction of the left ventricle. A post-hoc analysis of the PROactive study confirmed that although the incidence of serious CHF was increased with pioglitazone versus placebo, subsequent mortality or morbidity were not increased in pioglitazone-treated patients with serious CHF. 2 Nonetheless, because of the limited duration of observation after onset of CHF, longer term studies are needed to confirm that cardio vascular mortality is not an issue.
The controversy about thiazolidinediones should lead us to reconsider the place of these drugs in the management of type 2 diabetes mellitus. In an updated algorithm that followed the recent thiazolidinedione controversy, however, experts decided not to change the guidelines in the absence of definitive or compelling new data; thiazolidinediones still remain as one of three possible choices (sulfonylurea and insulin are the other two) that should be added to metformin and lifestyle intervention if target HbA 1c levels are not achieved. 3 Nevertheless, increased caution should be recommended in the use of thiazolidinediones, especially for patients at risk of CHF or those with pre-existing CHF. For patients with type 2 diabetes mellitus in whom the absolute risk of CHF is estimated to be low, the use of thiazolidinediones should be weighed against the risks and benefits of other antidiabetic medications. Caution is also advised in patients with prediabetes. 4 As highlighted by Lago et al., the true risk-benefit profile of a thiazolidinedione as compared with another treatment for type 2 diabetes mellitus should be assessed when all other cardiovascular risk factors (including glycemia) are similar in the two treatment groups. Large, long-term, head-to-head studies are, therefore, urgently needed to determine the comparative effects of the various pharmacological strategies on robust clinical end points in patients with type 2 diabetes mellitus. 5 
PRACTICE POINT
Increased caution is required in the use of thiazolidinediones for the management of type 2 diabetes mellitus, especially in patients with a history of congestive heart failure or in those at high risk of this disorder
